Novo Nordisk shares jump as Eli Lilly obesity pill disappoints

Go back to Novo Nordisk shares jump as Eli Lilly obesity pill disappoints

Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)

August 8, 2025 7:10 AM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,135.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "We believe we are at an inflection point for "The Broadening" of GLP-1 use, which will extend beyond US-based early adopters to... More